GI Doc Awakes to Bat in Mouth; Stopped Farting? Uh-Oh; FDA Approves GERD Implant
[post_content]
Disclaimer: This article has been automatically aggregated from
Virginia gastroenterologist Krista Edelman, MD, went viral on social media after revealing she woke up to a bat trying to burrow its way into her mouth. (People)
During colonoscopies, a second forward-view examination of the right colon with artificial intelligence assistance can improve adenoma detection rates, a randomized trial suggested. (American Journal of Gastroenterology)
One center’s electronic health record intervention yielded better adherence to guideline-recommended intervals for colonoscopy. (Gastro Hep Advances)
No longer farting? Black, shiny stool? Gastroenterologist Trisha Pasricha, MD, shared concerning signs that could warrant a trip to the emergency department. (Washington Post)
A randomized trial backed SI-449 — a cross-linked, powder-formed, chondroitin sulfate adhesion barrier system — as a new option during open rectal resections. (JAMA Surgery)
Too many kids with Crohn’s disease are being undertreated with 5-aminosalicylates, according to research in Clinical Gastroenterology and Hepatology.
New clues on intestinal inflammation, tissue regeneration, the extracellular matrix, and their links to inflammatory bowel diseases. (Immunity)
The case for using patient-reported outcomes to monitor Crohn’s disease activity in the clinic. (Gastro Hep Advances)
An Italian study in Crohn’s disease offered reassurance on switching from brand name ustekinumab (Stelara) to its biosimilars. (Clinical Gastroenterology and Hepatology)
A phase III trial of tezepelumab (Tezspire) for eosinophilic esophagitis met its co-primary endpoints, AstraZeneca and Amgen announced.
The FDA granted premarket approval to RefluxStop, a non-drug implant device for treating gastroesophageal reflux disease (GERD), according to maker Implantica.
In a phase II trial of metabolic dysfunction-associated steatohepatitis, a novel thyroid hormone receptor β agonist (ALG-055009) reduced liver fat without safety issues. (Lancet Gastroenterology & Hepatology)
Metabolic dysfunction-associated steatotic liver disease (MASLD) still isn’t on many people’s radar, according to U.K. survey data. (Clinical Gastroenterology and Hepatology)
Meanwhile, a study of patients screened for MASLD trials found that about one in 10 had phosphatidylethanol levels that would warrant evaluation for alcohol-related liver disease. (Clinical Gastroenterology and Hepatology)
In a study of U.S. veterans with hepatitis C-related decompensated cirrhosis, 13% achieved recompensation after starting direct-acting antivirals. (Clinical Gastroenterology and Hepatology)
The investigational selective immunoproteasome inhibitor zetomipzomib for difficult-to-treat autoimmune hepatitis showed promise in a phase II study. (Hepatology)
Research in the Journal of Hepatology examined 3-year outcomes in the phase III study that supported the approval of elafibranor (Iqirvo) for primary biliary cholangitis.
for informational purposes only. We do not claim ownership, accuracy, or liability for the content provided. All rights belong to the original publisher.